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 Context.—Genomic sequencing for cancer is offered by
commercial for-profit laboratories, independent laboratory
networks, and laboratories in academic medical centers
and integrated health networks. The variability among the
tests has created a complex, confusing environment.
Objective.—To address the complexity, the Personalized
Health Care (PHC) Committee of the College of American
Pathologists proposed the development of a cancer
genomics resource list (CGRL). The goal of this resource
was to assist the laboratory pathology and clinical
oncology communities.
Design.—The PHC Committee established a working
group in 2012 to address this goal. The group consisted of
site-specific experts in cancer genetic sequencing. The
group identified current next-generation sequencing
(NGS)–based cancer tests and compiled them into a usable
resource. The genes were annotated by the working group.
The annotation process drew on published knowledge,
including public databases and the medical literature.
Results.—The compiled list includes NGS panels offered
by 19 laboratories or vendors, accompanied by annota-
tions. The list has 611 different genes for which NGS-based
mutation testing is offered. Surprisingly, of these 611
genes, 0 genes were listed in every panel, 43 genes were
listed in 4 panels, and 54 genes were listed in 3 panels. In
addition, tests for 393 genes were offered by only 1 or 2
institutions. Table 1 provides an example of gene muta-
tions offered for breast cancer genomic testing with the
annotation as it appears in the CGRL 2014.
Conclusions.—The final product, referred to as the
Cancer Genomics Resource List 2014, is available as
supplemental digital content.
(Arch Pathol Lab Med. 2015;139:989–1008; doi:
10.5858/arpa.2014-0330-CP)
The last 10 years have seen a transformation in genomicmedicine and its application to cancer research and
clinical care.1,2 Comprehensive sequencing efforts have
identified at least 140 genes that are somatically mutated
in cancer,3 some of which can promote or drive tumorigen-
esis. In several cases, knowledge of driver mutations has led
to the development of specific inhibitors, which has
profoundly altered patient care.4,5 In addition to tumor-
specific mutations that define the response to a targeted
therapy, the same or other mutations in the tumor may be
associated with diagnosis6 and/or prognosis.7,8 Constitu-
tional variants may also have predictive, prognostic, or, in
some cases, diagnostic value (eg, germline cancer predis-
position variants).
Increased discoveries in cancer genomics have been
facilitated by a precipitous decline in the cost of sequencing.
Whole-genome sequencing, formerly a billion-dollar prop-
osition, can now be accomplished for $10 000 or less, and
the ‘‘$1000 exome’’ is becoming a reality. The time required
for sequencing has also decreased. Genomic data can now
be obtained in days rather than years, making this
information available in a clinically relevant time frame.
Therefore, interest in and demand for the integration of
genomic medicine into routine care has accelerated expo-
nentially, driven by diverse stakeholders including pathol-
ogists, oncologists, and their patients.9
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Table 1. Example of Gene Mutations Offered for Breast Cancer Genomic Testinga,b
Gene Tumor Type Mutation Type Expected Frequency
ABL1 Carcinoma Mutation, amplification (e7-1, Y459H, D501E, V741fs)
ABL2 Carcinoma Mutation, amplification (D227Y, R612K)
AKT1 Carcinoma Mutation, amplification (E17K [11], L52R) 2%–6%
AKT2 Carcinoma Mutation, amplification (E356K)
AKT3 Carcinoma Mutation, amplification (R66X, P310A, S375X)
ALK Carcinoma Mutation, amplification (G843R, R1275X,
FGM1271in_frame_delL)
AR Carcinoma Polymorphisms/germline mutation Rare
ATM Carcinoma Mutation Constitutional, no basal type
AURKA Carcinoma Polymorphism/constitutional single-nucleotide polymorphism
F31I
BRAF Carcinoma Mutation, amplification (K698R, L537S, E309X)
BRCA1 Carcinoma Mutation (many nonsense, frameshift, or missense mutations);
deletions
Constitutional, no HER2/neu
enriched, mostly basal
BRCA2 Carcinoma Mutation (many nonsense, frameshift, or missense mutations);
deletions
Constitutional, no HER2/neu
enriched
BRIP1 Carcinoma Mutation Constitutional, rare
CBFB Mutation 2%–4%
CCND1 Carcinoma Amplification (R260C mutation)
CCND3 Carcinoma Mutation
CDH1 Carcinoma Mutation 6.5% overall, 10% luminal A
CDK12 Carcinoma:
ER-positive
Silencing/inactivation of gene
CDK4 Carcinoma Amplification
CDK6 Carcinoma Amplification; mutation (H139Q)
CDKN1B Carcinoma Mutation
CHEK2 Carcinoma Mutation Constitutional
CTCF Carcinoma Mutation
DDR2 Carcinoma Mutation, amplification (S123I, E361D, A407P, K616N,
S674Y, R752H)
EPHA5 Triple negative Translocation Rare
ERBB2 Carcinoma Activating mutations, amplification/overexpression, decreased
phosphorylation (by PTPN12)
ERBB3 Carcinoma Mutations, amplification (F94L, Q153X, D297Y, T355I,
A378P, L783V, L792V, T1169P, E1261A)
ERBB4 Carcinoma Mutations, amplification (D73V, P172R, G500E, T703K,
E1205K, P1292S)
ESR1 Carcinoma Activating mutation in ligand-binding domain
ETV5 Carcinoma Multiple
EZH2 Carcinoma Increased expression
FANCC Carcinoma Single-nucleotide polymorphism Rare
FGFR2 Carcinoma rs11200014, rs2981579, rs1219648, rs2420946 (intron 2);
amplification in basal subtype
FGFR3 Carcinoma Mutation, amplification (P688S)
FGFR4 Carcinoma Mutation, amplification (E326K, A484T, E741fs)
GATA3 Carcinoma Mutation 4%–11% (47% luminal A,
32% luminal B)
GSTM5 Carcinoma Many nonsynonymous single-nucleotide polymorphisms
INHBA Multiple Promoter methylation changes, overexpression
JAK1 Carcinoma Mutation, amplification (G600W, K1090Q)
JAK2 Carcinoma Mutation, amplification (Y44X, L55P, R115I, Y132X, N646fs)
JAK3 Carcinoma Mutation, amplification (F110fs, R741Q)
KIT Carcinoma Mutation, amplification (P36T, I39M, A219V, A280V, G432E)
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Table 1. Extended
Gene
No. of
Panels in
Which Gene
Is Listedc Helpful Refs
Therapeutic,
Diagnostic,
Prognostic Target
(Yes, No, Unknown) Notes
ABL1 18 Unk, Unk, Unk
ABL2 2 Unk, Unk, Unk
AKT1 23 Banerji et al,151 2012; Cancer
Genome Atlas Network,18 2012
Yes, No, No
AKT2 6 Unk, Unk, Unk
AKT3 7 Unk, Unk, Unk
ALK 23 Unk, Unk, Unk
AR 4 Dimitrakakis and Bondy,152 2009 Yes, No, Yes
ATM 27 Unk, Unk, Unk
AURKA 4 Unk, No, No Therapeutic–hereditary breast cancer risk
BRAF 25 Chapman et al,104 2011; Sosman
et al,153 2012; Hauschild et
al,154 2012
Unk, Unk, Unk
BRCA1 13 Unk, Unk, Unk
BRCA2 13 Unk, Unk, Unk
BRIP1 9 Unk, Unk, Unk
CBFB 1 Banerji et al,151 2012; Cancer
Genome Atlas Network,18
2012
No, No, No
CCND1 4 Unk, Unk, Unk
CCND3 3 Unk, Unk, Unk
CDH1 27 Unk, Unk, Unk
CDK12 2 Iorns et al,150 2009 Yes, No, Yes Decreased CDK12 is associated with resistance
to tamoxifen, and possibly with increased
efficacy of PARP1/2 inhibitors
CDK4 8 Unk, Unk, Unk
CDK6 4 Unk, Unk, Unk
CDKN1B 2 Unk, Unk, Unk
CHEK2 10 Unk, Unk, Unk
CTCF 1 Unk, Unk, Unk
DDR2 8 Unk, Unk, Unk
EPHA5 3 Unk, Unk, Unk
ERBB2 20 Yes, Unk, Unk In situ hybridization is the clinically validated
technology for assessing ERBB2 amplification.
NGS-based methods must also probe the
centromere of chromosome 17 to distinguish
between polysomy 17 and amplification of
ERBB2; therapeutic–Y breast, gastric
ERBB3 4 Unk, Unk, Unk
ERBB4 15 Unk, Unk, Unk
ESR1 5 Toy et al,155 2013 Yes, No, No ER antagonists such as tamoxifen
ETV5 2 Oh et al,48 2012 Unk, Unk, Unk May be useful in prognosis
EZH2 15 Unk, No, No
FANCC 5 Thompson et al,156 2012 No, No, No Constitutional susceptibility in BRCA-negative
patients
FGFR2 19 Hunter et al,160 2007 Unk, Unk, Unk Predictive target
FGFR3 17 Unk, Unk, Unk
FGFR4 7 Unk, Unk, Unk
GATA3 3 Banerji et al,151 2012; Cancer
Genome Atlas Network,18
2012
No, No, No
GSTM5 1 Unk, Unk, Unk Part of polymorphic gastrointestinal stromal
tumor family, polymorphisms associated with
breast/prostate cancer
INHBA 1 Unk, Unk, Unk Involved in proliferation, overexpression
associated with poor prognosis
JAK1 5 Unk, Unk, Unk
JAK2 18 Unk, Unk, Unk
JAK3 16 Unk, Unk, Unk
KIT 23 Unk, Unk, Unk
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Table 1. Extended
Gene A B C D E1 E2 E3 E4 F G H1 H2 H3 H4 I1 I2 J1 J2 J3 J4 J5 J6 J7 J8
ABL1 Y Y Y Y Y Y N N Y Y N N N N Y Y N N N N N N N N
ABL2 N N N N Y N N N N Y N N N N N N N N N N N N N N
AKT1 N Y Y Y Y Y Y N Y Y Y Y N Y Y Y N N N N N N N N
AKT2 N Y Y N Y N N N N Y N Y N Y N N N N N N N N N N
AKT3 N Y Y Y Y N N N N Y N Y N Y N N N N N N N N N N
ALK Y Y Y Y Y Y Y N Y Y Y Y N N Y Y N N N N N N N N
AR N Y Y N Y N N N N N N N N N Y N N N N N N N N N
ATM Y Y Y Y Y Y N N Y Y N N N Y Y Y Y N Y N Y N Y N
AURKA N Y Y N Y N N N N Y N N N N N N N N N N N N N N
BRAF Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y N N N N N N N N
BRCA1 N Y Y Y N N N N N N N N N N N N Y Y Y N Y N Y N
BRCA2 N Y Y Y N N N N N N N N N N N N Y Y Y N Y N Y N
BRIP1 N Y Y N Y N N N N N N N N N N N Y N Y N Y N N N
CBFB N Y N N N N N N N N N N N N N N N N N N N N N N
CCND1 N Y Y N Y N N N N Y N N N N N N N N N N N N N N
CCND3 N Y Y N N N N N N N N N N N N N N N N N N N N N
CDH1 N Y Y Y Y Y N N Y Y N N N N N Y Y Y Y Y Y N N N
CDK12 N Y N N Y N N N N N N N N N N N N N N N N N N N
CDK4 N Y Y N Y N N N N Y N Y N N N N Y N N N N N N N
CDK6 N Y Y N Y N N N N Y N N N N N N N N N N N N N N
CDKN1B N Y Y N N N N N N N N N N N N N N N N N N N N N
CHEK2 N Y Y N Y N N N N Y N N N N N N Y N Y Y Y N N N
CTCF N Y N N N N N N N N N N N N N N N N N N N N N N
DDR2 N Y Y N Y N Y N N Y Y Y N N N N N N N N N N N N
EPHA5 N Y Y N N N N N N Y N N N N N N N N N N N N N N
ERBB2 Y Y Y Y Y Y Y N Y Y Y Y N N N Y N N N N N N N N
ERBB3 N Y Y N Y N N N N Y N N N N N N N N N N N N N N
ERBB4 N Y Y Y Y Y Y N Y Y N N N N N Y N N N N N N N N
ESR1 Y Y Y N Y N N N N Y N N N N N N N N N N N N N N
ETV5 N Y Y N N N N N N N N N N N N N N N N N N N N N
EZH2 N Y Y Y Y Y N N Y Y N N Y N N N N N N N N N N N
FANCC N Y Y N Y N N N N N N N N N N N N N N N N N N N
FGFR2 N Y Y Y Y Y Y N Y Y N N N N Y Y N N N N N N N N
FGFR3 N Y Y Y Y Y Y N Y Y N Y N N N N N N N N N N N N
FGFR4 Y Y Y N Y N N N N Y N N N N N N N N N N N N N N
GATA3 N Y Y N Y N N N N N N N N N N N N N N N N N N N
GSTM5 N N Y N N N N N N N N N N N N N N N N N N N N N
INHBA N Y N N N N N N N N N N N N N N N N N N N N N N
JAK1 N Y N N Y N N N N Y N N Y N N N N N N N N N N N
JAK2 Y Y Y Y Y Y N Y Y Y Y N Y N Y Y N N N N N N N N
JAK3 N Y Y Y Y Y N N Y Y N N Y N N Y N N N N N N N N
KIT Y Y Y Y Y Y N Y Y Y N Y Y Y N Y N N N N N N N N
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Table 1. Extended
Gene K L1 L2 L3 M1 M2 N1 N2 N3 N4 N5 N6 O P1 P2 Q R1 R2 R3 S1 S2
ABL1 Y Y N N N Y N N N N N N Y N Y N N Y N Y Y
ABL2 N N N N N N N N N N N N N N N N N N N N N
AKT1 Y Y N N N Y N N N N N N Y N Y Y N Y Y Y Y
AKT2 N N N N N N N N N N N N N N N N N N N N N
AKT3 N N N N N N N N N N N N N N N N N N N N N
ALK Y Y N N N Y N N N N N N Y N Y N Y Y Y Y Y
AR N N N N N N N N N N N N N N N N N N N N N
ATM Y Y N Y N Y N N N Y Y Y Y N Y N Y Y N N Y
AURKA N N N N N N N N N N N N N N N N N N N N N
BRAF Y Y N N N Y N N N N N N Y N Y Y N Y Y Y Y
BRCA1 N N N N N N Y N N Y Y Y N N N N Y N N N N
BRCA2 N N N N N N Y N N Y Y Y N N N N Y N N N N
BRIP1 N N N N N N N N N Y Y N N N N N Y N N N N
CBFB N N N N N N N N N N N N N N N N N N N N N
CCND1 N N N N N N N N N N N N N N N N N N N N N
CCND3 N N N N N N N N N N N N N N N N N N N N Y
CDH1 Y Y N Y Y Y Y N Y Y Y N Y N Y N Y Y Y N N
CDK12 N N N N N N N N N N N N N N N N N N N N N
CDK4 N N N N N N N N N N Y N N N N N Y N N N N
CDK6 N N N N N N N N N N N N N N N N N N N N N
CDKN1B N N N N N N N N N N N N N N N N N N N N N
CHEK2 N N N N Y N N N N N N N N N N N Y N N N N
CTCF N N N N N N N N N N N N N N N N N N N N N
DDR2 N N N N N N N N N N N N N N N N N N N Y N
EPHA5 N N N N N N N N N N N N N N N N N N N N N
ERBB2 Y Y N N N Y N N N N N N Y N Y N N Y Y Y N
ERBB3 N N N N N N N N N N N N N N N N N N N N N
ERBB4 Y Y N N N Y N N N N N N Y N Y N N Y N N N
ESR1 N N N N N N N N N N N N N N N N N N N N N
ETV5 N N N N N N N N N N N N N N N N N N N N N
EZH2 Y Y N N N Y N N N N N N Y N Y N Y N N N Y
FANCC N N N N N N N N N N N Y N N N N Y N N N N
FGFR2 Y Y N N N Y N N N N N N Y N Y N N Y Y Y Y
FGFR3 Y Y N N N Y N N N N N N Y N Y N N Y N Y Y
FGFR4 N N N N N N N N N N N N N N N N N N N Y Y
GATA3 N N N N N N N N N N N N N N N N N N N N N
GSTM5 N N N N N N N N N N N N N N N N N N N N N
INHBA N N N N N N N N N N N N N N N N N N N N N
JAK1 N N N N N N N N N N N N N N N N N N N N Y
JAK2 N Y N N N Y N N N N N N Y N N N N Y N N Y
JAK3 Y Y N N N Y N N N N N N Y N Y N N Y N N Y
KIT Y Y N N N Y N N N N N N Y N Y N Y Y Y Y Y
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Table 1. Continued
Gene Tumor Type Mutation Type Expected Frequency
LTK Carcinoma Mutation, amplification (E374D)
MAP2K4 Carcinoma Mutation 4% overall; 7% luminal A
MAP3K1 Carcinoma: luminal
A–type breast
cancer
R364G, H393fs, H393Q, S431fs, Q957stop, R1012fs,
L1052fs, M1269fs, E1286in_frame_del, S1344stop,
V1346in_frame_del, Q1494stop
3%–8%, (14%–15% of
luminal tumors)
MET Carcinoma Mutation, amplification (R412G, G225D,
(RS359in_frame_delPþ A361in_frame_delþ M362fs)
Low
MLL3 Carcinoma Mutation »7%
MYB Carcinoma Mutation Rare luminal A
NBN Carcinoma Mutation Constitutional
NF1 Carcinoma Mutation
NOTCH1 Carcinoma Polymorphisms, translocation 60% T-ALL
PDGFRA Carcinoma Mutation, amplification (E571K, R822H, R981P)
PDGFRB Carcinoma Mutation, amplification (D453E, R437H)
PIK3CA 27%–36% (45% in luminal A)
PIK3CB ER-positive tumors Amplification 0.05
PIK3R1 Carcinoma Most common mutations in region of 456–469 and 564–575
PTEN Carcinoma Mutation (e5-1, e6þ2, e6-2, E288fs, T319fs,
HY64in_frame_del, K128N, K266X); deletions
Constitutional, 3% overall
PTPRD Carcinoma Mutation
RAD50 Carcinoma Point mutations, small indels, large deletions Low
RAD51C Carcinoma Mutation Constitutional, basal
RB1 Carcinoma Mutation
ROS1 Carcinoma Mutation, amplification (S551F, E596K, e41þ2, N2234K,
T2266R)
RUNX1 Carcinoma Mutation 0.035
SF3B1 Carcinoma Mutation
SOCS1 Carcinoma Altered gene expression (higher in some cancers, while lower
in others), not well understood
SYK T-cell lymphoma-
positive
carcinoma
Translocation for T-cell lymphoma; heritable single-nucleotide
polymorphism for increased risk in breast cancer
7-fold increased risk in some
breast cancer populations
SYK Carcinoma Translocation for T-cell lymphoma; heritable single-nucleotide
polymorphisms for increased risk in breast cancer
7-fold increased risk in some
breast cancer populations
TLR4 Carcinoma Mutation Rare, ER-positive, HER2/neu-
negative
TNFAIP3 Carcinoma Overexpression
TP53 Carcinoma Mutation Constitutional, 27%–37%
(80% basal, 74% HER2/neu
enriched)
Abbreviations: ER, estrogen receptor; GIST, gastrointestinal stromal tumor; HER2/neu, gene for human epidermal growth factor receptor; N, no;
NGS, next-generation sequencing; PARP, poly-(ADP-ribose)-polymerase; Refs, references; T-ALL, T-cell acute lymphocytic leukemia; Unk, unknown;
Y, yes; A, Washington University (St Louis, Missouri) – Comprehensive Cancer Gene Set, v2; B, Foundation Medicine – FoundationOne (Cambridge,
Massachusetts); C, Brigham & Women’s Hospital (Boston, Massachusetts); D, Qiagen GeneRead DNAseq Human Comprehensive Cancer Panel
(Germantown, Maryland); E, Life Technologies Ion AmpliSeq (Carlsbad, California), E1: Comprehensive Cancer Panel, E2: Cancer Hotspot Panel v2,
E3: Colon and Lung Cancer Panel, E4: AML Panel; F, Baylor College of Medicine (Houston, Texas); G, University of Washington (Seattle, Washington)
– Oncoplex Panel; H, Knight Diagnostic Laboratories (Portland, Oregon), H1: GeneTrails NSCLC Genotyping Panel, H2: GeneTrails Solid Tumor
Panel, H3: GeneTrails AML MDS Genotyping Panel, H4: GeneTrails GIST Genotyping Panel; I, Caris Life Sciences (Irving, Texas), I1: Molecular
Intelligence for Solid Tumors, I2: Molecular Intelligence by Next-Generation Sequencing; J, Ambry Genetics (Aliso Viejo, California), J1:
CancerNext, J2: BRCAPlus, J3: BreastNext, J4: ColoNext, J5: OvaNext, J6: RenalNext, J7: PancNext, J8: PGLNext; K, ARUP Laboratories (Salt Lake
City, Utah) – Solid Tumor; L, Montefiore Medical Center (Bronx, New York), L1: Hot Spot, L2: Other somatic genes, L3: Other germline genes; M:
Mayo Medical Laboratories (Rochester, Minnesota), M1: Colorectal Cancer Panel, M2: 50-Gene Panel; N, Invitae (San Francisco, California), N1:
High-Risk Hereditary Breast Cancers, N2: High-Risk Hereditary Colon Cancers, N3: Hereditary Colon Cancer, N4: Women’s Hereditary Cancer, N5:
Hereditary Cancer, N6: Hereditary Pancreatic Cancer Panel; O, Johns Hopkins (Baltimore, Maryland); P, University of Pittsburgh Medical Center
(Pittsburgh, Pennsylvania), P1: ThyroSeq, P2: Solid Tumors; Q, Emory University (Atlanta, Georgia) – Snapshot; R, Illumina (San Diego, California),
R1: TruSight Cancer, R2: TruSeq Amplicon Cancer, R3: TruSight Tumor; S, PathGroup (Brentwood, Tennessee), S1: NGS for solid tumors, S2:
SmartGenomics Heme Gene List.
a Inclusion in the Cancer Genomics Resource List (CGRL) does not represent endorsement of a test by the College of American Pathologists. In
addition, the CGRL is purely descriptive and is not intended to provide consensus or expert opinion regarding the relative value of any given test or
gene. The CGRL is not intended to replace the detailed annotations required for test interpretation and/or patient management.
b This table represents data as of early May 2014. The panels offered by individual institutions are expected to change over time. Please check with
the institution for the most up-to-date offerings.
c This column calculates all the panels which the gene is listed in, not the number of institutions.
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Genomic data can be acquired via many methods,
including classical cytogenetics, in situ hybridization, and
microarray techniques. In addition, data supporting person-
alized medicine can be obtained by methods that might not
be considered ‘‘genomic’’ per se, such as immunohisto-
chemical staining.10 The revolution in genomic medicine,
however, has largely been driven by the development of
next-generation sequencing (NGS) technologies. Several
distinctive characteristics have made NGS a prominent
technique in contemporary genomic medicine:
1. The massively parallel nature of NGS allows large
amounts of sequence data to be acquired simultaneously
and at a low cost per nucleotide.
2. Next-generation sequencing is robust to specimen
deficiencies, such as DNA degradation, compared with
prior techniques.11
3. By producing many sequence reads over a given region,
NGS is highly sensitive and allows the detection of rare
alleles present within a mixed cellular population.12
4. The cost of NGS testing scales less than linearly with the
size of the assay: the costs of sequencing 50 and 500
genes with NGS differ by less than a factor of 10.
Therefore, the incremental cost of adding new genes to a
gene set is low.
5. Next-generation sequencing lends itself to a wide range
of methodologic adaptations that allow variations in the
assay size (whole-genome sequencing versus enrich-
ment methods), the analyte detected (DNA versus
messenger RNA versus epigenetic changes), and the
types of variants that can be detected (single-nucleotide
variants, insertions and deletions, copy number variants,
and structural variants).13
Table 1. Extended, Continued
Gene
No. of
Panels in
Which Gene
Is Listedc Helpful Refs
Therapeutic,
Diagnostic,
Prognostic Target
(Yes, No, Unknown) Notes
LTK 1 Unk, Unk, Unk
MAP2K4 5 Unk, Unk, Unk
MAP3K1 2 Ellis et al,149 2012 Unk, Unk, Unk
MET 22 Ghiso et al,162 2013 Unk, No, No Therapeutic–nonselective and selective tyrosine
kinase inhibitor; antihepatocyte growth factor
monoclonal antibodies
MLL3 1 Unk, Unk, Unk
MYB 2 Unk, Unk, Unk
NBN 8 Unk, Unk, Unk
NF1 12 Unk, Unk, Unk
NOTCH1 21 Unk, No, Unk Notch inhibitors are in early stages of evaluation;
therapeutic–potential; prognostic–chronic
lymphocytic leukemia conflicting data
PDGFRA 20 Cassier et al,157 2012 Unk, Unk, Unk
PDGFRB 5 Unk, Unk, Unk
PIK3CA 24 Banerji et al,151 2012; Cancer
Genome Atlas Network,18
2012
Yes, No, No
PIK3CB 1 Crowder et al,164 2009 Unk, Unk, Unk
PIK3R1 8 Unk, Unk, Unk
PTEN 36 Unk, Unk, Unk
PTPRD 3 Unk, Unk, Unk
RAD50 5 Weigman et al,158 2012 Unk, No, No Therapeutic–potentially yes; potentially sensitive
to PARP inhibitors
RAD51C 6 Unk, Unk, Unk
RB1 17 Unk, Unk, Unk
ROS1 6 Unk, Unk, Unk
RUNX1 12 Unk, Unk, Unk
SF3B1 7 Unk, Unk, Unk
SOCS1 4 Zhang et al,163 2012 No, No, No
SYK 2 Kanwal et al,161 2012 Yes, Yes, Yes Risk factor
SYK 2 Kanwal et al,161 2012 Yes, Yes, Yes Risk factor
TLR4 1 Unk, Unk, Unk
TNFAIP3 5 Vendrell et al,159 2007 No, No, No Overexpression associated with tamoxifen
resistance
TP53 39 Banerji et al,151 2012; Cancer
Genome Atlas Network,18
2012
No, Unk, Yes Diagnostic–maybe
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In current clinical practice, most NGS cancer testing
involves sequencing a panel or set of genes, rather than
the entire genome or exome. Sequencing entire genomes
or exomes produces a large volume of data without known
clinical significance. By focusing on a gene set of interest, a
test can achieve greater depth of coverage over regions of
interest while minimizing the total amount of sequencing
performed. This depth of coverage is particularly critical
for cancer testing because of tissue and tumor heteroge-
neity: somatic variants of interest may be present at a low
allele frequency, whereas in most constitutional testing,
variants are present at an allele frequency of either 50% or
100%.
Genomic sequencing for cancer care is now offered by
commercial for-profit laboratories, independent laboratory
networks, and clinical laboratories in academic medical
centers and integrated health care networks. There are
considerable differences between the tests offered by these
early adopters:
1. Some tests are custom-built by the laboratory, while
others are based on a vendor-designed kit.
2. Some tests are organ-specific (eg, a panel focusing on
lung cancer), while others are relevant to multiple
different organs.
3. Different sequencing platforms are used (with most tests
using technology from either Illumina [San Diego,
California] or Ion Torrent [Life Technologies, Carlsbad,
California]).
4. The tests also differ in enrichment methodology, the
major distinction being hybrid capture versus amplifica-
tion.
Table 1. Extended, Continued
Gene A B C D E1 E2 E3 E4 F G H1 H2 H3 H4 I1 I2 J1 J2 J3 J4 J5 J6 J7 J8
LTK N N N N Y N N N N N N N N N N N N N N N N N N N
MAP2K4 N Y Y Y Y N N N N Y N N N N N N N N N N N N N N
MAP3K1 N Y Y N N N N N N N N N N N N N N N N N N N N N
MET Y Y Y Y Y Y Y N Y Y N Y N N N Y N N N N N Y N N
MLL3 N N N N Y N N N N N N N N N N N N N N N N N N N
MYB N N Y N Y N N N N N N N N N N N N N N N N N N N
NBN N N Y N Y N N N N N N N N N N N Y N Y N Y N N N
NF1 N Y Y Y Y N N N N Y N Y N Y N N Y N Y N Y N N Y
NOTCH1 Y Y Y Y Y Y Y N Y Y Y Y Y N Y Y N N N N N N N N
PDGFRA Y Y Y Y Y Y N N Y Y N N N Y Y Y N N N N N N N N
PDGFRB N Y Y Y Y N N N N Y N N N N N N N N N N N N N N
PIK3CA Y Y Y Y Y Y Y N Y Y Y Y N Y Y Y N N N N N N N N
PIK3CB N N N N Y N N N N N N N N N N N N N N N N N N N
PIK3R1 N Y Y Y Y N N N N Y Y Y N N N N N N N N N N N N
PTEN Y Y Y Y Y Y Y N Y Y Y Y N Y Y Y Y Y Y Y Y Y N N
PTPRD N N N N Y N N N N Y Y N N N N N N N N N N N N N
RAD50 N Y N N Y N N N N N N N N N N N Y N Y N Y N N N
RAD51C N N N N N N N N N N N N N N N N Y N Y N Y N N N
RB1 Y Y Y Y Y Y N N Y Y N Y N N N Y N N N N N N N N
ROS1 N Y Y Y Y N N N N Y N N N N Y N N N N N N N N N
RUNX1 Y Y Y Y Y N N Y N Y N N Y N N N N N N N N N N N
SF3B1 N Y Y N Y N N N N Y N N Y N N N N N N N N N N N
SOCS1 N Y Y Y Y N N N N N N N N N N N N N N N N N N N
SYK N N Y N Y N N N N N N N N N N N N N N N N N N N
SYK N N Y N Y N N N N N N N N N N N N N N N N N N N
TLR4 N N N N Y N N N N N N N N N N N N N N N N N N N
TNFAIP3 N Y Y Y Y N N N N N N N N N N N N N N N N N N N
TP53 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N
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The variability among the currently available tests has
created a complex environment, which may be confusing to
clinicians and pathologists as both users and as developers
of NGS cancer testing. To address this complexity, in 2009,
the Personalized Health Care (PHC) Committee of the
College of American Pathologists (CAP) proposed the
development and synthesis of a cancer genomics resource
list. The goal was to develop a list of cancer gene panels
offered by early-adopter academic and commercial labora-
tories operating in CAP-accredited, Clinical Laboratory
Improvement Amendments of 1988 (CLIA)–certified envi-
ronments. The PHC Committee established the Core
Cancer Panel Working Group in 2012 to address this goal.
The present article, including the accompanying Table 1
representing breast cancer genetic mutations and associated
Web site, is the product of that working group’s efforts.
METHODS
Members of the working group were selected by the chair for
their expertise in NGS testing and their knowledge of particular
disease genes. The task force included a specialist in each of the
major organ systems.
The working group members used their professional knowledge
to identify academic pathology departments and reference labora-
tories offering NGS testing in the fall of 2013. One large
community-based practice was included. Each laboratory was
queried to determine the genes included in the test or tests offered.
These gene lists were posted on some laboratories’ Web sites; in
other cases, they were provided by laboratory directors. When
information was obtained via a Web site, the vendor or
organization was contacted to confirm the information’s accuracy
and timeliness. The gene lists were periodically reconfirmed with
the laboratories, and any changes were incorporated (last update
May 5, 2014).
Table 1. Extended, Continued
Gene K L1 L2 L3 M1 M2 N1 N2 N3 N4 N5 N6 O P1 P2 Q R1 R2 R3 S1 S2
LTK N N N N N N N N N N N N N N N N N N N N N
MAP2K4 N N N N N N N N N N N N N N N N N N N N N
MAP3K1 N N N N N N N N N N N N N N N N N N N N N
MET Y Y N N N Y N N N N Y N Y N Y N Y Y Y Y N
MLL3 N N N N N N N N N N N N N N N N N N N N N
MYB N N N N N N N N N N N N N N N N N N N N N
NBN N N N N N N N N N Y Y N N N N N Y N N N N
NF1 N N N N N N N N N N N N N N N N Y N N N N
NOTCH1 Y Y N N N Y N N N N N N Y N Y N N Y N N Y
PDGFRA Y Y N N N Y N N N N N N Y N Y N N Y Y Y Y
PDGFRB N N N N N N N N N N N N N N N N N N N N N
PIK3CA Y Y N N N Y N N N N N N Y N Y Y N Y Y Y Y
PIK3CB N N N N N N N N N N N N N N N N N N N N N
PIK3R1 N N N N N N N N N N N N N N N N N N N Y N
PTEN Y Y N Y Y Y Y N Y Y Y N Y N Y Y Y Y Y N Y
PTPRD N N N N N N N N N N N N N N N N N N N N N
RAD50 N N N N N N N N N N N N N N N N N N N N N
RAD51C N N N N N N N N N Y Y N N N N N Y N N N N
RB1 Y Y N N N Y N N N N N N Y N Y N Y Y N N N
ROS1 N N N N N N N N N N N N N N N N N N N N N
RUNX1 N N Y N N N N N N N N N N N N N Y N N Y Y
SF3B1 N N Y N N N N N N N N N N N N N N N N N Y
SOCS1 N N N N N N N N N N N N N N N N N N N N N
SYK N N N N N N N N N N N N N N N N N N N N N
SYK N N N N N N N N N N N N N N N N N N N N N
TLR4 N N N N N N N N N N N N N N N N N N N N N
TNFAIP3 N N N N N N N N N N N N N N N N N N N N Y
TP53 Y Y N Y Y Y Y N Y Y Y Y Y N Y N Y Y Y N Y
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The gene lists offered by these early adopters were compiled into
a table (Table 1; and supplemental digital content including
Supplemental Tables 1 and 2, available for this article at www.
archivesofpathology.org in the August 2015 table of contents)
without additions or deletions. The genes were then annotated by 1
or more working group members. Specifically, each member
reviewed the table to identify genes relevant to his or her assigned
organ system. Because a single gene may have different effects in
different diseases, the working group created a separate row for
each annotated gene-disease pair. The annotation process drew on
published knowledge, including public databases and the medical
literature. The data elements extracted for each gene-disease pair
are listed in Table 2. Not all elements were abstracted for all gene-
disease pairs. In addition, genes that were present in only 1 or 2
panels were considered to have insufficient uptake to justify the
effort required to annotate them. These are listed in Supplemental
Table 2.
The working group chair reviewed the table as a whole for
quality assurance. The final product, henceforth referred to as the
Cancer Genomics Resource List 2014 (CGRL), is available as
supplemental digital content at www.archivesofpathology.org in
the August 2015 table of contents. A Table of only those genes
offered for breast cancer mutation testing is included in the article
as Table 1. The Resource List was current as of May 5, 2014;
however, the working group recognizes that all the elements of the
table will change over time. Inclusion in the CGRL does not
represent endorsement of a test by the CAP. In addition, the CGRL
is purely descriptive and is not intended to provide consensus or
expert opinion regarding the relative value of any given test or
gene. The CGRL is not intended to replace the detailed annotations
required for test interpretation and/or patient management. The
references were derived from a number of sources, including the
following CAP Pathology Resource Guides: Genomic Analysis and
Molecular Diagnosis, CAP SPECs (Short Presentations in Emerging
Concepts) references, and journal articles.
RESULTS
The working group consisted of site-specific experts in
cancer genetic sequencing and early adopters of NGS
technology. This group identified current NGS-based cancer
tests for inclusion in the CGRL (Table 3).
The gene lists obtained from these laboratories and
vendors, accompanied by the annotations produced as
described in ‘‘Methods,’’ were aggregated into the CGRL
(available as Cancer Genomics Resource List 2014). The
CGRL can be sorted according to any column. Some users
may choose to sort by organ system or tumor type: this view
provides a useful reference for those interested primarily in a
specific subset of cancers (Figure 1). Sorting by gene is also
particularly useful for easily assessing the known signifi-
cance of a given gene across tumor types.
The number of genes per panel ranged from 6 (Ambry
Genetics’ [Aliso Viejo, California] BRCAplus and Invitae’s
[San Francisco, California] High-Risk Hereditary Breast
Cancers) to 408 (Life Technologies’ Ion AmpliSeq Compre-
hensive Cancer Panel) (Figure 2). The CGRL includes 611
different genes for which NGS-based mutation testing is
offered. Surprisingly, of these 611 genes, 0 genes were listed
in every panel, 43 genes were listed in 4 panels, and 54
genes were listed in 3 panels (Figure 3). In addition, tests for
393 genes were offered by only 1 or 2 institutions. Mutations
in these genes are quite rare. The working group annotated
the 218 genes that were included in 3 or more panels and
chose not to annotate the remaining genes (Figure 4).
Table 3. Laboratory-Developed and Vendor-Developed Panels Included in the Cancer Genomics Resource List 2014
Laboratory/Vendor Test Name
Washington University (St Louis, Missouri) Comprehensive Cancer Gene Set, v2
Foundation Medicine (Cambridge, Massachusetts) FoundationOne
Brigham and Women’s Hospital (Boston, Massachusetts)
Qiagen (Germantown, Maryland) GeneRead DNAseq Human Comprehensive Cancer Panel
Life Technologies (Carlsbad, California) Ion AmpliSeq Comprehensive Cancer Panel, Ion AmpliSeq Cancer
Hotspot Panel v2, Ion AmpliSeq Colon and Lung Cancer Panel, Ion
AmpliSeqAML Panel
Baylor College of Medicine (Houston, Texas)
University of Washington (Seattle, Washington) Oncoplex Panel
Knight Diagnostic Laboratories (Portland, Oregon) GeneTrails NSCLC Genotyping Panel, GeneTrails Solid Tumor Panel,
GeneTrails AML MDS Genotyping Panel, GeneTrails GIST Genotyping
Panel
Caris Life Sciences (Irving, Texas) Solid Tumors, Next-Generation Sequencing
Ambry Genetics (Aliso Viejo, California) CancerNext, BRCAPlus, BreastNext, ColoNext, OvaNext, RenalNext,
PancNext, PGLNext
ARUP Laboratories (Salt Lake City, Utah) Solid Tumor
Montefiore Medical Center (Bronx, New York) Hot Spot, other somatic genes, other germline genes
Mayo Medical Laboratories (Rochester, Minnesota) Colorectal Cancer Panel, 50-Gene Panel
Invitae (San Francisco, California) High-Risk Hereditary Breast Cancers, High-Risk Hereditary Colon
Cancers, Hereditary Colon Cancer, Women’s Hereditary Cancer,
Hereditary Cancer, Hereditary Pancreatic Cancer Panel
Johns Hopkins University (Baltimore, Maryland)
University of Pittsburgh (Pennsylvania) ThyroSeq, Solid Tumor
Emory University (Atlanta, Georgia) Snapshot
Illumina (San Diego, California) TruSight Cancer, TruSeq Amplicon Cancer, TruSight Tumor
PathGroup (Brentwood, Tennessee) NGS (Next-Generation Sequencing) for Solid Tumors, SmartGenomics
Heme Gene List
Table 2. Data Elements Abstracted for Gene-Disease
Pairs
Organ system
Specific tumor type
Mutation type and position
Expected mutation frequency
Significance (diagnostic, therapeutic, prognostic)
Associated drug, for therapeutically significant genes
References
Number of panels in which gene is listed
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Breast Cancer
Breast cancer is not a single disease; rather, its molecular
and clinical characteristics vary substantially.14,15 Gene
expression profiling has been used to identify early breast
cancer cases with such a low risk of recurrence after local
therapy and antihormonal therapy that the addition of
adjuvant chemotherapy would provide little benefit.16,17 The
Cancer Genome Atlas (TCGA) recently performed a
comprehensive molecular analysis of more than 500 breast
cancers; only 3 genes (TP53, PIK3CA, and GATA3) mutated
in more than 10% of the tumors were identified. Commonly
altered genes included TP53, PIK3CA/PTEN, and RB1;
however, the mechanisms of alteration were quite variable
and included mutations, deletions, amplifications, and copy
number alterations.18 The Molecular Taxonomy of Breast
Cancer International Consortium assessed 2000 cases of
breast cancer and identified 10 subgroups with unique gene
expression, genomic profiles, and clinical outcomes, dem-
onstrating that the frequency of mutations was variable
among the different subgroups.19,20 Although these findings
are not yet actionable, it is hoped that they will facilitate a
more personalized approach to breast cancer in the near
future. Table 1 provides a detailed list and the annotation of
the genes associated with breast cancer included in the
CGRL.
Gastrointestinal—Gastric Cancer
Gastric cancers carry numerous genomic aberrations that
result in the development and progression of carcinogen-
esis.21,22 However, few genomic alterations currently have
demonstrated clinical value. Genomic alterations in gastric
cancers that have been validated or are in advanced stages
of evaluation for clinical application include HER2/neu
expression and amplification as well as MET and FGFR
amplification.
A randomized phase 3 clinical trial (ToGA trial) estab-
lished the utility of targeting HER2/neu in advanced gastric
cancer23 by demonstrating that metastatic gastric or
gastroesophageal adenocarcinomas positive for HER2/neu
amplification or overexpression showed improved overall
survival in trastuzumab-treated subjects. Testing HER2/neu
expression and amplification status and adding trastuzumab
to the chemotherapy regimen for advanced HER2/neu-
positive gastric and esophageal cancers has become the
standard of care. The overexpression and amplification of
HER2/neu has been described in 6% to 35% of gastric and
gastroesophageal junction adenocarcinomas.24,25 HER2/neu
amplification in gastric carcinoma is associated with poor
outcome25–27 and has been shown to be an independent
prognostic factor.24 The CAP reviewed the current guide-
Figure 1. Number of institutions offering
gene panels containing from 1 to more than
300 genes. Each bar shows the number of
genes that were offered by the stated number
of laboratories.
Figure 2. Number of genes offered by each
institution. The institutions include the follow-
ing: Ambry Genetics, Aliso Viejo, California;
ARUP Laboratories, Salt Lake City, Utah;
Baylor College of Medicine, Houston, Texas;
Brigham and Women’s Hospital, Boston,
Massachusetts; Caris Life Sciences, Irving,
Texas; Emory University, Atlanta, Georgia;
Foundation Medicine, Cambridge, Massachu-
setts; Illumina, San Diego, California; Invitae,
San Francisco, California; Johns Hopkins
University, Baltimore, Maryland; Knight Diag-
nostic Laboratories, Portland, Oregon; Life
Technologies, Carlsbad, California; Mayo
Medical Laboratories, Rochester, Minnesota;
Montefiore Medical Center, Bronx, New York;
PathGroup, Brentwood, Tennessee; Qiagen,
Germantown, Maryland; University of Wash-
ington, Seattle, Washington; University of
Pittsburgh Medical Center (UPMC), Pitts-
burgh, Pennsylvania; and Washington Uni-
versity, St Louis, Missouri. Abbreviations:
Labs, Laboratories; Univ, University.
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lines for the interpretation of HER2/neu expression and
amplification.23,27,28
Other promising molecular targets in advanced gastric
cancer include the overexpression and amplification of the
MET and FGF receptors. MET- and FGFR-targeted therapies
are being evaluated in phase 3 trials. MET amplification
defines a small (2% of tested cases) but aggressive subset of
gastric and esophageal adenocarcinomas, suggesting sensi-
tivity to the targeted MET inhibitor crizotinib.29 FGFR2 gene
amplification, which was detected in 2% of tested gastric
tumors, predicts sensitivity to the selective fibroblast growth
factor receptor (FGFR) inhibitor AZD4547.30
In contrast to colorectal cancer, anti–epidermal growth
factor receptor (EGFR) therapies (cetuximab, panitumumab,
and gefitinib) failed to improve the outcomes of gastric
cancer patients in phase 3 trials.31 In addition, EGFR
pathway gene mutations failed to predict resistance to
anti-EGFR targeted therapies.32
Gastrointestinal—Colorectal Cancer
The most important driver genes of colorectal carcino-
genesis have been identified, although the systematic
incorporation of this information into a set of clinically
useful markers for prognosis or the prediction of suscepti-
bility to therapeutic agents has proven elusive.33,34 However,
a recent review of mutations identified by the TCGA
colorectal cancer study found a high incidence (70%) of
cancers with potentially ‘‘druggable’’ mutations.35 The most
important mutations linked to known therapeutic benefits
in colon cancer were in exons 2, 3, and 4 of KRAS and NRAS.
The absence of a KRAS or NRAS mutation implies an intact
EGFR-MAPK pathway that is potentially susceptible to anti-
EGFR therapy. A therapeutic response generally increases
survival by only a few months on average.36 A BRAF
mutation (V600E) in microsatellite-stable colon cancer is
associated with a poor outcome but is not a universally
accepted predictive marker of anti-EGFR therapy.37
Gastrointestinal—Pancreatic Cancer
Numerous genetic alterations are involved in the molec-
ular carcinogenesis of pancreatic adenocarcinoma. Genes
that are frequently mutated in pancreatic cancer include
KRAS, CDKN2A (p16), TP53, and SMAD4/DPC4.37 In
addition to these key genes, numerous other genetic
mutations have been identified that impact various cellular
pathways involved in pancreatic carcinogenesis and can
potentially serve as theranostic targets. Some of the mutated
genes that have been identified in pancreatic cancer and
have been added to clinical testing panels include MLL3,
TGFBR2, ARID1A, SF3B1, ATM, and ARID2.38 The GATA4
gene product was found to be overexpressed by immuno-
histochemical testing of pancreatic ductal adenocarcino-
ma.39 Two genes, KLF6 and NFKBIZ, were identified as part
of a 6-gene panel used to predict the survival of patients
with localized pancreatic ductal adenocarcinoma; both of
these genes showed higher expression in the poor prognosis
group.40 Immunohistochemical analyses revealed that ele-
vated tumor expression of the proteins encoded by 2 genes,
ERCC1 and RRM1, was associated with poor prognosis41;
these genes may serve as potential biomarkers for person-
alized chemotherapy. Studies of patients with pancreatic
cancer treated with gemcitabine have suggested that tumors
with high RRM1 expression portended a better prognosis
than those with low RRM1 expression,42 and ovarian cancer
studies have suggested that tumors with high ERCC1
expression had a poor response to platinum-based thera-Figure 4. Number of genes relevant in multiple tumor types.
Figure 3. Number of genes annotated as being clinically significant at various disease sites. Abbreviations: CNS, central nervous system; GI,
gastrointestinal; Heme, hematologic; Neuro; neurological.
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py.43 Although some of the genes mentioned above appear
to have prognostic utility, none of these genes or their
protein products are currently useful in the diagnosis of
pancreatic adenocarcinoma, nor are they currently approved
as theranostic markers.
Intraductal papillary mucinous neoplasms (IPMNs) can
give rise to pancreatic adenocarcinoma; however, these
cystic lesions are often difficult to diagnose preoperatively.
Three genes included in clinical testing panels may be of
diagnostic utility. Inactivating mutations in STK11, a tumor
suppressor gene, have been identified in IPMNs but not in
another known mucinous precursor lesion, pancreatic
intraepithelial neoplasia.44 Activating mutations in PIK3CA,
which have been found in a minority of IPMNs, may
identify a specific variant called intraductal tubulopapillary
neoplasm.45 Finally, more than 40% of IPMNs harbor
mutations in GNAS (and often in KRAS as well), a feature
that can be of diagnostic utility in preoperative cyst fluid
analyses46 because other cystic pancreatic lesions do not
appear to harbor GNAS mutations.44
Genitourinary—Prostate Cancer
Approximately 50% of all primary prostate cancers
possess TMPRSS2:ERG rearrangements.47 Several other
ERG rearrangements have been reported in prostate cancer,
including rearrangements involving the ETS family mem-
bers ETV1 (7p21.2) and ETV4 (17q21) as well as the RAF
kinase gene.48–52 The subsequent overexpression of the ERG
protein is virtually 100% specific for the presence of prostate
cancer in surgical specimens.53,54 SPOP is the most
frequently mutated gene in prostate cancer studies, with
mutations found in 6% to 15% of cases across multiple
independent cohorts.55,56 Recurrent genetic alterations in
prostate cancer frequently involve genes that mediate AR
signaling, common tumor suppressors, and chromatin
modification genes. The activation of the PI3K and RAS/
RAF signaling pathways occurs in approximately 42% of
prostate cancers.57 SPINK1 mutations define an aggressive
molecular subtype of ETS fusion–negative prostate cancers
and account for approximately 10% of all prostate cancers.58
EZH2 is significantly upregulated in prostate cancer and is
associated with cancer aggressiveness.59 Other genetic
alterations associated with prostate cancer include the loss
of NKX3.1 and PTEN as well as mutations in AR, AKT1,
TP53, RB1, and PIK3CA.55,57,60,61
Genitourinary—Bladder Cancer
The most important driver mutations of urothelial bladder
carcinoma occur in FGFR3 and TP53, which define 2 distinct
pathways in urothelial bladder carcinoma.62 FGFR3 muta-
tions are associated with low-stage, low-grade, superficial
papillary tumors with favorable disease characteristics and
lower rates of recurrence and progression; TP53 mutations
occur in up to 70% of muscle-invasive bladder cancers and
are associated with high-stage, high-grade tumors.63 Car-
cinoma in situ has a high rate of TP53 mutations,64 and the
following genetic mutation rates have been reported for
urothelial carcinoma: PIK3CA, 26%; CDKN2A/B, 23%; RB1,
17%; CCND1, 14%; FGFR1, 14%; CCND3, 11%; FGFR3,
11%; MDM2, 11%; EGFR, 6%; and HER2/neu, 6%.65 Other
genetic alterations have been identified in bladder carcino-
genesis, including mutations in RAS gene family members
and in TERT, as well as the loss of the RB1 and PTEN tumor
suppressors.63,66–68 With the exception of genes such as
FGFR3, TP53, RB1, HER2/neu, CDKN2A, VEGF, and PTEN,
most of the identified alterations have not been related to
outcome or treatment response; thus, their roles require
further refinement.60,63
Gynecologic Cancers
The genetic tests identified by this working group
included approximately 40 genes with specific relevance to
gynecologic cancers, particularly endometrial and ovarian
cancers. Many of these genes have functions in multiple
tumor types and sites; for example, the tumor suppressor
gene PTEN is commonly mutated in endometrioid cancers
of both the endometrium and ovary. Several important
genes in gynecologic cancers—for example, PTEN, ARID1A,
and HER2/neu—may exhibit somatic mutations in numerous
regions of the gene, making a sequencing-based approach
more attractive than hotspot testing or single-nucleotide
genotyping. Several targeted therapies for gynecologic
cancers are either in current use or in advanced stages of
development, including tyrosine kinase inhibitors for
FGFR2-mutated tumors, PARP inhibitors69–71 for tumors
with ‘‘BRCAness,’’ 72,73 and mTor inhibitors for tumors with
mutations in the PI3K/mTor/Akt pathway.74–76 Next-gener-
ation sequencing testing is therefore positioned to play an
important role in therapy selection for cancers of this organ
system.
Head and Neck Cancers
Most head and neck cancers are squamous cell carcino-
mas, which are often associated with human papillomavirus
(HPV) infection or with alcohol and tobacco use.77 Head and
neck squamous cell carcinomas (HNSCCs) are heteroge-
neous tumors with mutational patterns that differ between
HPV-positive and HPV-negative tumors.78 The mutational
rate of non–HPV-related HNSCCs is comparable to that of
other smoking-related malignancies and is approximately
double that of HPV-related HNSCCs.78 Recently, molecular
subtypes of HNSCCs were identified by using expression
profiling.79 Most cases of HNSCC exhibit high EGFR
expression due to amplification (approximately 17% of
cases) or posttranslational modifications. Genetic alterations
in the PIK3/AKT/mTOR pathway, which is downstream of
EGFR, are also often identified in HNSCCs (74% of cases).80
PIK3CA is of particular interest because inhibitors are
already under development for breast cancer treatment.
Several salivary gland neoplasms and HNSCCs are associ-
ated with translocations, including MECT1/MAML t(11;19)
in mucoepidermoid carcinoma, MYB/NFIB t(6;9) in adenoid
cystic carcinoma, ETV6/NTRK3 t(12;15) in mammary analog
secretory carcinoma, and EWSR/ATF1 t(12;22) in clear cell
carcinoma. As research in the role of genetic translocations
in head and neck cancers continues to develop, additional
significant genes are likely to be identified.
Head and Neck—Thyroid Cancer
Thyroid cancer is the most common malignancy of
endocrine organs, and its incidence is increasing steadily
in the United States and worldwide. It is clinically important
to establish a thyroid cancer diagnosis preoperatively and to
separate thyroid nodules that are malignant and need to be
surgically removed from benign nodules that do not require
surgery. It is also important to predict aggressive behavior of
well-differentiated thyroid cancers and to select appropriate
therapies for dedifferentiated tumors. Performing NGS of
genes involved in thyroid carcinogenesis can address these
challenges.81 The most common mutations in papillary
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thyroid cancer (PTC) are point mutations of the BRAF and
RAS genes and rearrangements of RET/PTC, NTRK1, and
NTRK3 (a recent discovery), all of which are able to activate
the mitogen-activated protein kinase (MAPK) pathway.
These mutations are found in more than 70% of PTCs.81–85
RAS mutations and PAX8/PPARGc rearrangements, which
are also mutually exclusive, have been identified in 70% to
75% of follicular thyroid carcinomas.81,86 Genetic alterations
involving the PI3K/AKT signaling pathway have also been
observed in thyroid tumors, particularly in advanced and
dedifferentiated tumors.81,87–89 Additional mutations known
to occur in poorly differentiated and anaplastic carcinomas
involve the TP53, AKT1, and CTNNB1 genes. Medullary
thyroid carcinomas, both familial and sporadic, frequently
carry point mutations in the RET and RAS genes.81,90,91 All of
these genetic alterations are helpful for establishing a
diagnosis of malignancy in thyroid fine-needle aspiration
(FNA) samples.81 In addition, mutations in some genes (eg,
BRAF and TERT) are associated with a more aggressive
tumor phenotype and can be used as prognostic mark-
ers.92,93 Finally, a number of known (BRAF, RET) and
recently discovered (STRN-ALK) mutational markers may
guide the selection of targeted therapies for aggressive types
of thyroid cancer.94
Hematologic Malignancies
Many clinically relevant and disease-dependent alter-
ations in hematologic malignancies are translocations. In
acute myeloid leukemias and myeloproliferative neoplasms,
the presence of a specific translocation determines malig-
nancy and is used to identify the category and subtype of
leukemia, as outlined by the World Health Organization
Classification of Tumours.95 For example, a translocation such
as the Philadelphia chromosome, t(9;22)(q34;q11), which
involves the BCR and ABL genes, is required for diagnosis of
chronic myelogenous leukemia. In addition to diagnostic
information, identifying the BCR/ABL translocation provides
important information about the patient’s prognosis and
response to the ABL kinase-specific drug imatinib. A
diagnosis of acute promyelocytic leukemia requires the
identification of the t(15;17)(q24:q12); PML/RARA re-
arrangement or related rearrangements. The response to
trans retinoic acid and anthracycline depends on which
specific translocation is present. The clinically relevant
translocations involved in all the subtypes of myeloid
neoplasms are too numerous to describe here.
Myeloid malignancies are also associated with many
prognostically and therapeutically important inactivating
and activating mutations, short deletions, and duplications
that affect the clinical course and can be identified by using
NGS. These include alterations in FLT3, NPM1, CEBPA, c-
KIT, IDH1, IDH2, TET2, MLL, DNMT3A, JAK2, RUNX1, and
many more.96
Translocations are a diagnostic and prognostic feature of
many lymphoid malignancies of mature and immature T
and B cells. Translocations involving the immunoglobulin
heavy-chain or j or k light-chain genes, on chromosome 14,
2, and 22, respectively, are observed in B-cell malignancies.
Furthermore, translocations involving the T-cell receptor a,
b, k, or d genes, on chromosomes 14(q11), 7(q35-6), 7(p15),
and 14(q11), respectively, are observed in T-cell malignan-
cies. The translocation partners are extremely varied and are
either diagnostic or prognostic in many cases. Many other
partners are classically found in B-cell and T-cell malignan-
cies. The hallmark translocations t(8;14)(q24;32),
t(14;16)(q32;q21), and t(11;14)(q13;32) are associated with
Burkitt lymphoma, follicular lymphoma, and mantle cell
lymphoma, respectively. Single-nucleotide variants are not
commonly found in malignant lymphomas.95,97
Translocations are frequently used as diagnostic and
prognostic markers for different subtypes of precursor B
and T lymphoblastic leukemia/lymphoblastic lymphoma.
The following translocations are observed in precursor B
lymphoblastic leukemia/lymphoma: t(12;21)(p13;q22) in-
volving TEL/AML1 (16%–29% of cases), t(1;19)(q23;p13.3)
involving PBX/E2A (6% of cases), t(4;11)(q21;q23) involving
AF4/MLL (2%–3% of cases), and t(9;22)(q34;q11.2) involv-
ing BCR/ABL (3%–4% of cases). Each translocation confers a
different clinical phenotype and prognosis, and clinical
decisions are influenced by the identification of these
specific abnormalities. Mutations in CRLF2, IKZL1, TP53,
ERG, and NOTCH have also been detected in precursor B
and T lymphoblastic leukemia/lymphoblastic lymphoma
and confer an adverse prognosis.96,97 Many additional
translocations have been identified in patients with T
lymphoblastic leukemia/lymphomas, but these have not
been linked to diagnostic subtype, prognosis, or therapy as
abnormalities in precursor B lymphoblastic leukemia/lym-
phoblastic lymphoma have.
In contrast to lymphomas, mature B-cell lymphoid
malignancies, chronic lymphocytic leukemia (CLL), and
hairy cell leukemia are associated with characteristic
deletions, insertions, chromosome duplications, and muta-
tions, which define disease progression and clinical prog-
nosis. The most common aberrations in CLL include 13q
deletion, trisomy 12, and deletions of 11q, 17p, or 6q. Many
other genes are commonly mutated in CLL, including the
following: NOTCH1; XPO1 (exportin 1); MYD88; KLH6
(Kelch-like 6); TP53; TGM; BIRC3; PLEKHG5; ATM; SF3B1
(splicing factor 3, B1 unit); ZMYM3; MAPK1; FBXW7; and
DDX3X. Mutations in these genes often confer a worse
prognosis.98–100
The identification of the BRAF V600E mutation in almost
100% of hairy cell leukemia cases has refined the diagnosis,
prognosis, and therapeutic strategies for this disease.101 This
mutation is found only rarely in multiple myeloma or other
B-cell malignancies.
Lung Cancer
Lung adenocarcinoma is one of the highest profile cancers
for which NGS is beneficial. Several critical, mutually
exclusive ‘‘driver’’ oncogenes have been found to render
some lung cancers susceptible to treatment with specific
targeted inhibitors. The first discovered and largest (~20%)
group of lung adenocarcinomas carry mutations in exons 18
to 21 of EGFR. Among these tumors, approximately 80%
respond radiographically to treatment with targeted inhib-
itors of the EGFR tyrosine kinase domain (TKIs), such as
gefitinib or erlotinib, with a resulting increase in progres-
sion-free survival in advanced-stage lung cancer from
approximately 6 months to approximately 15 months.
However, these patients inevitably relapse, often with either
a secondary mutation in EGFR exon 20 or with a copy
number gain of the MET oncogene, although other
mechanisms have been reported. Following the discovery
of EGFR, similar responses were reported for tumors that
contained ALK (~5%) or ROS1 (~1%) rearrangements and
were treated with an ALK TKI. Other small subsets of
patients with lung adenocarcinomas have been reported to
bear rearrangements of RET, NTRK1, or FGFR1/2/3, or
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mutations involving HER2/neu, BRAF, or PIK3CA; each of
these populations is currently being studied for its response
to specific targeted inhibitors, with promising preliminary
results.
By contrast, less is known concerning squamous cell or
small cell carcinomas of the lung. These cancers do not
appear to contain the same alterations or exhibit the same
responses to targeted therapies as adenocarcinomas. There
have been recent reports of squamous cell carcinomas of the
lung bearing several recurrent alterations, including copy
number gains or, less commonly, mutations in the FGFR
genes and in DDR2. Case reports of responses to targeted
inhibitors have been published, and clinical trials are
ongoing.
Melanoma
Melanoma can be divided into multiple genetic subsets by
mutations that are generally mutually exclusive. The BRAF
V600 mutation in exon 15 is present in up to half of
cutaneous melanoma cases, which can be treated with US
Food and Drug Administration–approved inhibitors,102–106
for which clinical trials are underway to determine the best
therapy.107–109 Both NRAS and BRAF mutations may also
carry prognostic significance.110–113 Another subset of
melanoma cases exhibit a loss of NF1, which encodes a
RAS-GTPase (guanosine triphosphatase)–activating protein
that normally inactivates the wild-type RAS protein; the loss
of NF1 increases the activation of pathways downstream of
RAS.114,115 Up to 20% of mucosal and acral lentiginous
melanomas, which are very rare compared with cutaneous
cases, possess activating mutations and/or amplification of
the KIT locus on 4q12.116,117 Such cases can be treated with
the appropriate tyrosine kinase inhibitors.118 Because KIT,
NRAS, and NF1 mutations in melanomas tend to activate
both the ERK and AKT pathways to some degree, these
mutations are generally mutually exclusive.114,119,120 BRAF
mutations primarily activate the ERK pathway, but a
complementary loss of PTEN or other events can concom-
itantly activate AKT in these tumors.108 One-third of
cutaneous melanomas lack mutations in any of these genes,
but many show a variety of genetic events that activate the
ERK and AKT pathways. Uveal melanomas adopt an
alternative genetic route, with activating mutations in
GNAQ and GNA11, which encode a subunits of heterotri-
meric G proteins that activate phospholipase signaling
pathways.121,122 Melanomas commonly contain mutations in
other genes, such as CDKN2A, TP53, and other, more novel
genes; however, no targeted therapies have been developed
for such cases.114,119,120,123 Multiplex genetic testing ap-
proaches are increasingly used to assign patients to the
targeted therapy approaches that are best suited to their
specific mutations. Mutational profiles may also facilitate the
selection of immune activation treatments, which show
great promise in melanoma.124–126
Nervous System Tumors
Although there are a wide range of central nervous system
tumors, genetic changes are particularly relevant in neuro-
blastomas and gliomas. MYCN amplification is a well-
known genetic abnormality in neuroblastoma, but somatic
mutations are found in only a small number of tumors.127,128
ALK mutations are the most common somatic mutation in
neuroblastoma and represent a potential therapeutic target.
In low-grade gliomas, the most relevant genetic changes are
the codeletion of 1p and 19q and IDH1 mutations, both of
which are associated with a better prognosis and the
oligodendroglial phenotype.129 Numerous genetic changes
have been found in glioblastoma multiforme (GBM). Many
of these changes are not unique to GBM but are common in
other cancers (PTEN, P53, EGFR, PDGFRA, and PIK3CA);
others, such as TERT mutations and MGMT promoter
methylation, are more specific to GBM.130 MGMT promoter
methylation leads to the silencing of MGMT and predicts
treatment response and prognosis.131
Sarcomas
Sarcomas, whether occurring in soft tissues, the gastro-
intestinal tract, reproductive organs, or elsewhere, are
associated with translocations that produce functional
fusion genes.132 Although the presence of a particular
translocation is not an absolutely sensitive or specific
indicator of a given diagnosis, a limited set of translocations
is characteristic of many sarcomas. Consequently, testing for
chromosomal rearrangements has been incorporated into
sarcoma treatment guidelines.133 Unfortunately, it is difficult
to identify translocations by using chromosomal DNA
sequence analyses (either traditional Sanger methods or
NGS approaches) because the breakpoints that produce the
rearrangements occur within different introns of the
involved genes in regions that are at least several kilobases
long.134 Consequently, interphase fluorescence in situ
hybridization or reverse transcriptase–polymerase chain
reaction are the laboratory methods most commonly used
to detect translocations. However, NGS methods can be
used to identify translocations with the appropriate ‘‘wet-
lab’’ assay design and bioinformatic analysis, most com-
monly using a hybrid capture approach.135,136 The develop-
ment of targeted therapies directed against specific proteins
in the intracellular cascades activated by the fusion gene–
encoded chimeric proteins has promoted interest in testing
for characteristic translocations in sarcomas to guide therapy
rather than merely to guide diagnosis.
In addition, single-nucleotide variants (eg, inactivating
mutations in hSNF5/INI1) and short indels (eg, short in-
frame deletions in KIT) are increasingly recognized as
characteristic of other sarcoma types. In contrast with
translocations, these mutation types can readily be identified
by using both NGS approaches and traditional sequencing
methods. For some tumor types (eg, gastrointestinal stromal
tumors), specific mutations are correlated with the response
to particular therapeutic agents.137 Furthermore, because the
mutations that allow some tumors to escape primary
therapy have been categorized, it is sometimes possible to
use targeted therapy even in the context of recurrent
disease.137
COMMENT
The goal of developing this comprehensive list of cancer
gene panels offered by early NGS adopters was to assist the
laboratory pathology communities. The main audience to
which our effort was targeted included the current and next
waves of pathologist adopters of targeted large panels for
cancer, based on the NGS platform. This list will provide the
greatest benefits for academic and large reference laborato-
ries, although large pathology groups and hospital systems
will also benefit. The rapid availability of the list will assist in
the development of laboratory-developed tests for individ-
ual use. Pathologists could design a gene panel by using the
data included in the CAP cancer resource list and adding
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other genes specific to the interest of their institution. For-
profit reference laboratories can use the panel to develop in
vitro diagnostic medical device kits, and pharmaceutical
companies can use it to develop clinical trials. Finally, both
hematologists/oncologists and patients might find the list
useful. Therefore, the resource list is expected to benefit
current pathology adopters, the next wave of pathology
adopters, and all the members of the pathology and
molecular diagnostic communities, including providers and
patients.
Multigene NGS tests have been described by using
various terms, including gene set and panel. The term panel
has been criticized by payers and regulators owing to
concerns related to test bundling. When clinicians can order
multiple separate tests by checking a single box, they may
become desensitized to the cost of the individual tests or to
the possibility of ordering less than the full panel.138 Indeed,
anecdotal evidence indicates that payers have refused to
approve NGS panels on the grounds that they represent
unnecessary test bundling. However, we submit that the
term panel has a special meaning in the NGS context.
Instead of representing a grouping of multiple individually
orderable tests, a multigene NGS panel represents a single
test that encompasses multiple genomic regions. Most
critically, eliminating individual genes from an NGS panel
does not significantly reduce the cost of the assay. The
blanket rejection of these tests on the semantic grounds that
they represent ‘‘panels’’ obscures real questions that remain
about the optimal design of these tests. We therefore
propose the re-adoption of panel as a valid and useful term
to describe multigene NGS assays.
In selecting genes for inclusion in clinical genomics
assays, some laboratories have chosen to create disease-
specific gene sets (eg, ‘‘lung genes’’ for lung cancer), while
others have designed a single ‘‘pan-cancer’’ test appropriate
for all cancer types. Each of these approaches has
advantages and disadvantages.
Among the laboratories surveyed by the CGRL Working
Group, Knight Diagnostic Laboratories at Oregon Health
and Science University (Portland)139 exemplifies the disease-
specific approach; this laboratory offers a specific NGS test
for non–small cell lung cancer, another for gastrointestinal
stromal tumors, and another for leukemia. Similarly, the
University of Pittsburgh Medical Center (Pittsburgh, Penn-
sylvania) has developed a specific panel for the preoperative
diagnosis of thyroid cancer.81 Ambry Genetics has also
created a series of cancer site-specific NGS tests,140 although
these tests are designed to detect constitutional cancer
predisposition variants. The disease-specific approach has
the advantage of reducing the size of the assay, potentially
allowing higher throughput through greater sample multi-
plexing. The identified variants in a focused gene set are
relatively more likely to have been discussed in the literature
in the context of the patient’s tumor type; that is, the
significance of identified variants is more likely to be known.
Focused gene sets also reduce exposure to incidental
variants.
Pan-cancer tests have also been implemented in several of
the laboratories we surveyed, including Washington Uni-
versity (St Louis, Missouri)141 and Foundation Medicine
(Cambridge, Massachusetts).142 These tests include a larger
group of genes, all of which are associated with actionable
variants in some tumor type. Arguments in favor of this
approach include simplified development; a single assay
need only be validated once, whereas multiple disease-
specific assays require multiple validation procedures. The
laboratory workflow is also simpler with a pan-cancer test
than with multiple site-specific tests. More importantly, by
sequencing genes that are not canonically mutated in the
patient’s cancer type, one increases the probability of
discovering unexpected variants. Indeed, the promise of
precision medicine is that the mutational profile of a
patient’s tumor may be more important than the tumor’s
site of origin or direction of differentiation.143 Because the
cost of testing is an important consideration, it is
noteworthy that the cost of NGS-based assays does not
scale directly with the number of genes tested; the costs of
sequencing targeted sets of 15 or 50 genes are similar. Thus,
the difference in assay size between disease-specific tests
and pan-cancer tests is not accompanied by a proportionate
increase in cost.
A detailed description of the strategies for validating NGS
panel tests is beyond the scope of this article, but several
general points are worth mentioning. First, NGS panel tests
are fundamentally similar to every other laboratory test and
thus require a formal analysis of factors such as their
sensitivity, specificity, reproducibility, and reference range.
Second, NGS panel tests involve 2 separate components: a
wet-lab component (for DNA extraction, library prepara-
tion, and actual sequence generation) and an in silico
component (the bioinformatic process by which variants are
identified and annotated), both of which require formal
validation.144–147 Third, several regulatory agencies have
promulgated requirements for validation, and it is clear that
different validation approaches fulfill these require-
ments.141,142,148
Available gene panels for NGS may be either prede-
signed by the manufacturers of sequencing platforms or
designed by individual users. Predesigned gene panels are
easier and faster to validate and implement in a clinical
laboratory because the manufacturer performs the initial
troubleshooting and library optimization, provides step-
by-step instructions for the sequencing process, and
frequently supplies the analytic pipeline for data interpre-
tation. However, the library design, gene selection, and
bioinformatics pipeline are ‘‘locked’’ by the manufacturer.
By contrast, custom gene panels allow flexibility in
choosing an optimal methodologic approach (eg, hybrid
capture versus amplification-based sequencing) and in
selecting an appropriate sequencing platform. Custom
panels allow the inclusion of a variable number of genes
(targets) of interest according to the goals of the panel, and
they allow the user to modify the panel as new targets
become available. The development and validation of a
custom panel can be tedious and time consuming. This
process begins with reviews of the PubMed (US National
Library of Medicine, Bethesda, Maryland) literature and
various mutation databases to identify the genes, exons, or
hotspots of interest. The genomic coordinates for these
alterations must be submitted to a manufacturer for the
synthesis of primers for a target amplification-based library
or for hybrid capture probes. Next, extensive troubleshoot-
ing of the panel’s accuracy and performance characteristics
(such as depth and uniformity of coverage and reads on
target) is performed; suboptimal results might require the
redesign of the entire panel. Finally, more extensive
validation is required for custom gene panels, including
validation of the ‘‘wet’’ sequencing part and the custom
bioinformatics pipeline.
1004 Arch Pathol Lab Med—Vol 139, August 2015 The Cancer Genomics Resource List 2014—Zutter et al
The greatest challenge associated with performing NGS
tests is the clinical interpretation of the results. For most
tested genes, there is a finite and relatively small number of
variants with well-established clinical significance (eg, the
BRAF V600E mutation in melanoma and the EGFR L858R
mutation in lung adenocarcinoma). When performing NGS
of cancer samples, particularly when a matched constitu-
tional sample is not available, these few, well-established
mutations represent a small percentage of the alterations
detected by the analysis. Most of the discovered mutations
are of unclear significance, presenting the reporting
laboratory with a conundrum: how much effort should be
invested in analyzing the importance of each of these
mutations?
Numerous informatics tools are available to assist with
these interpretations: published literature searches, data-
bases of mutations reported previously in cancer or in
constitutional samples from healthy volunteers, in silico
functional prediction tools that analyze the likely functional
and structural consequences of the amino acid changes
encoded by the mutation, and assessments of the conser-
vation of a given nucleotide through evolution. Ultimately,
however, none of these tools are sufficient for a definitive
assessment. The laboratory quality health care provider
issuing the report must synthesize this information and
render a personal, professional opinion. An automated
knowledge base can store these interpretations so that the
next time a gene mutation–disease pair is encountered, time
is saved; nonetheless, the effort required for the initial
interpretations is significant.
An alternative is to interpret only the mutations that have
a well-established meaning and to present the remainder as
a list of variants of uncertain significance. This approach
places the onus for interpreting these results on the
practitioner who receives the report, who may not be well
equipped to perform this function within the time con-
straints of a clinical practice. If the practitioner cannot
interpret the variants of uncertain significance or explain
their meaning to patients, some patients will undoubtedly
attempt to interpret them themselves, relying heavily upon
Web-based resources.
One potential solution would be a shared knowledge
base, similar to the existing databases that catalog the
presence of mutations in various genes in various tumors. In
this instance, however, the functional relevance of these
mutations would be included. Currently, each institution
performing NGS is compiling its own private knowledge
base, leading to parallelized efforts. A coordinated, cooper-
ative effort would be more efficient in the long run. This
problem will only be magnified exponentially when
technology advances from panels of a few hundred genes
to the entire exome and genome.
In summary, the PHC Committee of the CAP developed a
cancer genomics resource list to assist the laboratory
pathology and clinical oncology communities. The CGRL
provides a table listing the genes offered by 19 laboratories
and vendors, accompanied by annotations. The entire list is
available as Cancer Genomics Resource List 2014 as
supplemental digital content. A subset of the genes
associated with breast cancer and their annotations are
included as Table 1.
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